Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with...
Zynerba Pharmaceuticals
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and...
| EPIC: | ZYNE |
| Market: | NASDAQ:ZYNE |
| 52-week High/Low: | $12.50 / $2.82 |
| Sector: | Pharma & Biotech |
| Market Cap: | $92.01M |
| Website: | zynerba.com |
col 3
col 4
col 5
col 6
Zynerba Pharmaceuticals Snapshot
Videos
Partners:
